Clinical Trial Update: Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating cabozantinib in combination with nivolumab and ipilimumab for advanced non-clear cell renal cell carcinoma (NCCRCC), in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chromophobe Renal Cell Carcinoma
• Collecting Duct Renal Cell Carcinoma
• Papillary Renal Cell Carcinoma
• Renal Cell Carcinoma
• Translocation Renal Cell Carcinoma
• Unclassified Renal Cell Carcinoma
• Unresectable Advanced Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bradley A. McGregor, MD | Conditions: Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING